|
Expand your vocabulary – and your horizons
These days you can stick an “e” in front of almost anything. Remember when this all started? It began, what seems like a lifetime ago, when “e-mail” became a part of our lives.
I now use the word “e-business” for what we used to call “e-commerce.” To me, “e-business” is a broader term that includes any business activity that is, or can, be conducted on the Web. And when it comes to e-business for pharma, a whole new slew of “e-words” have become part of my vocabulary: “e-sales and marketing,” “e-research,” “e-administration,” “e-healthcare,” etc.
At a recent e-Biopharm conference, Mark Robillard, Senior Vice President of EMAX Solutions, reportedly cautioned: “...
Click for full story
--Lisa Roner, Editor, eyeforpharma Briefing
AstraZeneca selects IntraLinks to facilitate clinical trials
IntraLinks, an application service provider that enables B2B collaboration over the Internet, recently announced that AstraZeneca is using its digital workspaces for document management and information exchange in clinical drug trials, including a current oncology project.
According to John Assaro, Senior Account Executive at IntraLinks, AstraZeneca is using IntraLinks’ secure, online environment to exchange documents and data among scientists and physicians involved in its global clinical trials. The digital workspaces, which can be established in less than four hou...
Click here for Full Story
First Genetic Trust: Banking Genetic Information
In these days of human genome sequencing and gene patenting, much of the excitement of discovery is being tempered by cautionary warnings on the need for establishing boundaries for the ethical use of an individual’s genetic information. And while consumers are concerned about how to protect their genetic identities, drug companies and medical researchers want to ensure they continue to have access to the genetic information required for the development of next- generation pharmaceutical products.
Arthur Holden, chairman and CEO of the SNP Consortium, saw this collision course of differing agendas as a business opportunity in the making and has co-founded a new company – a “genetic bank” – with a mission of managing and protecting genetic data.
According to Holden, First Genetic Trust i...
Click here for Full Story
To
comment on this newsletter or add your own content please
email Shabnam at shabnam@firstconf.com
To subscribe for the eyeforpharma Briefing, email:
EYEFORPHARMA-SUBSCRIBE-REQUEST@PEACH.EASE.LSOFT.COM
To unsubscribe, email:
EYEFORPHARMA-SIGNOFF-REQUEST@PEACH.EASE.LSOFT.COM
Disclaimer - First Conferences and its agents used their best
efforts in collecting and preparing the information published
herein. However, First Conferences does not assume, and hereby
disclaims, any and all liability for any loss or damage caused
by errors, whether such errors resulted from negligence, accident,
or other causes.
|
|
|
